Krystal Biotech Reports Positive KB113 Data in Gorlin Syndrome; FDA Talks Begin

summarizeSummary

Krystal Biotech's KB113 produced broad basal cell carcinoma regression in a three-patient Gorlin syndrome pilot study, with responses in non-injected lesions and no serious adverse events. The company has begun FDA discussions for advanced development of the program.

check_boxKey Events · Product Development and Regulatory · KRYS

• KB113 Pilot Study Data Positive

  In three Gorlin syndrome patients, 83.1% (69/83) of assessed landmark basal cell carcinoma lesions regressed, with 50.6% (42/83) showing greater than 50% regression and 9.6% (8/83) at least 90% regression.

• Abscopal Effect Observed

  85.1% (40/47) of non-injected lesions regressed, including 57.4% with greater than 50% regression, indicating systemic immune-mediated tumor clearance beyond the injection site.

• Complete Responses Confirmed Histologically

  One injected lesion per patient achieving at least 90% clinical regression was biopsied; all three showed histologically confirmed complete response with no residual tumor.

• Safety Profile Clean

  All 22 reported adverse events were mild or moderate, transient, and resolved; no serious adverse events occurred.

auto_awesomeAnalysis · KRYS · Life Sciences

KB113 is a new intratumoral immunotherapy program, and this is its first clinical readout in Gorlin syndrome. Over 80% of 83 assessed lesions regressed, including 85% of lesions that were never injected — preliminary evidence of a systemic (abscopal) immune effect. All three biopsied lesions showed histologically confirmed complete response, and there were no serious adverse events. The company has already opened FDA discussions for advanced development, so this is a pipeline expansion with a defined next step rather than a one-off data point. The caveat is size: three patients and a single-arm pilot cannot establish efficacy, and the program is early relative to the commercial VYJUVEK business.